These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7742033)

  • 1. Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain.
    Neurath AR; Lin K; Strick N; Jiang S
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):189-90. PubMed ID: 7742033
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
    Jin BS; Ryu JR; Ahn K; Yu YG
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
    Wild CT; Shugars DC; Greenwell TK; McDanal CB; Matthews TJ
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9770-4. PubMed ID: 7937889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence.
    Jiang S; Lin K
    Pept Res; 1995; 8(6):345-8. PubMed ID: 8838418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
    Cai L; Jiang S
    ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane-perturbing domains of HIV type 1 glycoprotein 41.
    Mobley PW; Pilpa R; Brown C; Waring AJ; Gordon LM
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):311-27. PubMed ID: 11242518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
    Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
    Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
    [No Abstract]   [Full Text] [Related]  

  • 12. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H; Qiu Z; Su Y; Yang L; He Y
    AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking HIV entry.
    Buzko OV; Shokat KM
    Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
    Seo JK; Kim HK; Lee TY; Hahm KS; Kim KL; Lee MK
    Peptides; 2005 Nov; 26(11):2175-81. PubMed ID: 15876473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
    Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K
    J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
    Shi W; Cai L; Lu L; Wang C; Wang K; Xu L; Zhang S; Han H; Jiang X; Zheng B; Jiang S; Liu K
    Chem Commun (Camb); 2012 Dec; 48(94):11579-81. PubMed ID: 23093045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
    Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
    D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
    Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
    J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B; Tian YS; Utachee P; Sapsutthipas S; Isarangkura-na-Ayuthaya P; Auwanit W; Takagi T; Ikuta K; Sawanpanyalert P; Kawashita N; Kameoka M
    Virology; 2010 Sep; 405(1):157-64. PubMed ID: 20580393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.